Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 329

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 329
---
 its request, to the fullest extent permitted by Delaware law. Delaware
law generally provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably
believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable
cause to believe such person’s conduct was unlawful;

●we may, in our discretion, indemnify employees and agents in
those circumstances where indemnification is permitted by applicable law;

●we are required to advance expenses, as incurred, to our directors
and officers in connection with defending a proceeding, except that, if required by the DGCL, such directors or officers shall undertake
to repay such advances if it is ultimately determined that such person is not entitled to indemnification;

●we are not obligated pursuant to the Amended Bylaws to indemnify
a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings
authorized by our board of directors or brought to enforce a right to indemnification; and

●the rights conferred in the Amended Bylaws are not exclusive,
and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance
to indemnify such persons.

The outbreak of new, novel diseases, similar to the world’s
recent experience with COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.

In December 2019, a novel strain of the coronavirus disease, COVID-19,
was identified in Wuhan, China. The virus spread globally and government measures taken in response had a significant impact, both direct
and indirect, on businesses and commerce, resulting in worker shortages, disruption of supply chains, and closure of offices, laboratories,
and production facilities. Demand for certain goods and services, such as medical services and supplies, spiked, while demand for other
goods and services, such as travel, fell dramatically. If a new disease began to spread, we may experience disruptions that could severely
impact our business, including:

●interruptions in preclinical studies due to restricted or limited
operations at our laboratory facilities or at facilities of our collaborators;

●interruption of, or delays in receiving, supplies for preclinical
studies and/or clinical trials from our Contract Research Organizations (“CROs”), Contract Manufacturing Organizations (“CMOs”)
or other collaborators due to staffing shortages, production slowdowns or stop